Source link : https://www.newshealth.biz/health-news/doxorubicin-trabectedin-strategy-boosts-survival-in-challenging-sarcoma/
Treatment with doxorubicin plus trabectedin (Yondelis), followed by trabectedin maintenance, improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic or unresectable uterine or soft-tissue leiomyosarcoma compared with doxorubicin alone, a randomized phase III trial showed. Among 150 patients, median OS was 33 months in the combination group versus 24 months in the […]
Author : News Health
Publish date : 2024-09-04 21:00:00
Copyright for syndicated content belongs to the linked Source.
